Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes

Kidney International

Volumn 87, Issue 1, 2015, Pages 20-30

  Molitch, Mark E ^a   Adler, Amanda I ^b   Flyvbjerg, Allan ^c   Nelson, Robert G ^d   So, Wing Yee ^e   Wanner, Christoph ^f   Kasiske, Bertram L ^g   Wheeler, David C ^h   De Zeeuw, Dick ⁱ   Mogensen, Carl E ^j  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c AARHUS UNIVERSITY   (Denmark)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g HENNEPIN COUNTY MEDICAL CENTER   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Albuminuria; blood pressure; diabetic kidney disease; glycemic control; lipid management

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MINERALOCORTICOID ANTAGONIST; PLACEBO; ROSUVASTATIN; TACROLIMUS;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG CHOICE; EARLY INTERVENTION; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEALTH CARE PLANNING; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACIDOSIS; MICROALBUMINURIA; MORTALITY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK REDUCTION; SCREENING; SODIUM RESTRICTION; TREATMENT OUTCOME; COMPLICATION; DIABETIC NEPHROPATHIES; DISEASE COURSE; HYPERGLYCEMIA;

ALBUMINURIA; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; HYPERTENSION;

EID: 84920272288     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.128     Document Type: Conference Paper

References (113)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of The diabetes epidemic. Nature 2001; 414: 782-787.
2. Hemmelgarn BR, Manns BJ, Lloyd A et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.
3. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
4. van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-1352.
5. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
6. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
7. So WY, Kong AP, Ma RC et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006; 29: 2046-2052.
8. Molitch ME, Steffes M, Sun W et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in The diabetes control and complications trial and The epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33: 1536-1543.
9. The DCCT Research Group. Effect of intensive therapy on The development and progression of diabetic nephropathy in The Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47: 1703-1720.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
12. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents The progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
13. Breyer JA, Bain RP, Evans JK et al. Predictors of The progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996; 50: 1651-1658.
14. Mulec H, Blohme G, Grande B et al. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 1998; 13: 651-655.
15. Nathan DM, Zinman B, Cleary PA et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-1316.
16. Nyberg G, Blohme G, Norden G. Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 1987; 30: 82-86.
17. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
18. Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of The ACCORD randomised trial. Lancet 2010; 376: 419-430.
19. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
20. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
21. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
22. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in The irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037.
23. Cooper-DeHoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61-68.
24. Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369.
25. Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: W13-W14.
26. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
27. Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1090-1099.
28. Navaneethan SD, Pansini F, Perkovic V et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009 CD007784.
29. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
30. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
31. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
32. Nye HJ, Herrington WG. Metformin: The safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118: c380-c383.
33. Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010; 15: 412-418.
34. Rachmani R, Slavachevski I, Levi Z et al. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002; 13: 428-433.
35. Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-1340.
36. Newman DJ, Mattock MB, Dawnay AB et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9: iii-ivxiii-163.
37. Hayes AJ, Leal J, Gray AM et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from The 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013; 56: 1925-1933.
38. Palmer SC, Craig JC, Navaneethan SD et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 263-275.
39. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49: S1-S180.
40. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical Practice Guidelines: Chronic Kidney Disease in Diabetes. Can J Diabetes 2013; 37: S129-S136.
41. National Collaborating Centre for Chronic Conditions. Clinical Guideline 66. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). Royal College of Physicians: London, UK, 2008; 278 pp.
42. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes. A National Clinical Guideline. Scottish Intercollegiate Guidelines Network (SIGN): Edinburgh, UK, 2010; 170 pp. (SIGN publication; no. 116).
43. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-S63.
44. Boulware LE, Jaar BG, Tarver-Carr ME et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101-3114.
45. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of The renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
46. Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011; 20: 246-257.
47. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839.
48. Shastri S, Katz R, Shlipak MG et al. Cystatin C and albuminuria as risk factors for development of CKD stage 3: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2011; 57: 832-840.
49. Peralta CA, Shlipak MG, Judd S et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305: 1545-1552.
50. Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380: 807-814.
51. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673.
52. de Boer IH, Katz R, Cao JJ et al. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care 2009; 32: 1833-1838.
53. de Jong PE, Gansevoort RT. Is cystatin C The answer to detecting progression in CKD? J Am Soc Nephrol 2011; 22: 9-11.
54. Altman DG, McShane LM, Sauerbrei W et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.
55. American Diabetes Association. Clinical Practice Recommendations 2012. Diabetes Care 2012; 35(Suppl 1): S1-S110.
56. de Boer IH, Sun W, Cleary PA et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376.
57. Holman RR, Paul SK, Bethel MA et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
58. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
59. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
60. Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171: 1920-1927.
61. Ramirez SP, McCullough KP, Thumma JR et al. Hemoglobin A(1c) levels and mortality in The diabetic hemodialysis population: findings from The Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care 2012; 35: 2527-2532.
62. Ricks J, Molnar MZ, Kovesdy CP et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes 2012; 61: 708-715.
63. Duong U, Mehrotra R, Molnar MZ et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011; 6: 1041-1048.
64. Yates CJ, Fourlanos S, Hjelmesaeth J et al. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant 2012; 12: 820-828.
65. Molnar MZ, Huang E, Hoshino J et al. Association of pretransplant glycemic control with posttransplant outcomes in diabetic kidney transplant recipients. Diabetes Care 2011; 34: 2536-2541.
66. Zeitler P, Hirst K, Pyle L et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247-2256.
67. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-371.
68. Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010 CD002967.
69. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in The setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437.
70. British National Formulary. Available at: www.bnf.org (accessed 15 November 2011).
71. Japanese Society of Nephrology. Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease. Tokyo Igakusha: Tokyo, Japan, 2012.
72. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for The Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150.
73. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
74. Venstrom JM, McBride MA, Rother KI et al. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003; 290: 2817-2823.
75. Gruessner RW, Sutherland DE, Kandaswamy R et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation 2008; 85: 42-47.
76. Scalea JR, Butler CC, Munivenkatappa RB et al. Pancreas transplant alone as an independent risk factor for The development of renal failure: a retrospective study. Transplantation 2008; 86: 1789-1794.
77. Fioretto P, Steffes MW, Sutherland DE et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.
78. Fioretto P, Najafian B, Sutherland DE et al. Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients. Clin J Am Soc Nephrol 2011; 6: 101-106.
79. Upadhyay A, Earley A, Lamont JL et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 251-262.
80. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet 2007; 370: 1829-1839.
81. Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
82. Colhoun HM, Betteridge DJ, Durrington PN et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from The Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810-819.
83. Tonelli M, Jose P, Curhan G et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332: 1426.
84. Shepherd J, Kastelein JJ, Bittner V et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448-1454.
85. Holdaas H, Holme I, Schmieder RE et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 2011; 22: 1335-1341.
86. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Guideline on The Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of The American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; doi:10.1016/j.jacc.2013.11.002.
87. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kindey Int Suppl 2013; 3: 259-305.
88. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031.
89. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for The Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 337-414.
90. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012; 60: 850-886.
91. Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol 2010; 21: 1086-1092.
92. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on The 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013; 62: 201-213.
93. Systolic Blood Pressure Interventional Trial (SPRINT). Available at:. http://www.clinicaltrials.gov/ct2/show/nct01206062, (accessed 2 January 2014).
94. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
95. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of The angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
96. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in The Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
97. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of The HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
98. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
99. Hou FF, Xie D, Zhang X et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898.
100. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
101. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
102. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
103. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
104. Fried LF, Duckworth W, Zhang JH et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009; 4: 361-368.
105. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for The treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903.
106. Haller H, Ito S, Izzo JL Jr. et al. Olmesartan for The delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
107. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578.
108. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on The development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
109. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
110. Ekinci EI, Clarke S, Thomas MC et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 2011; 34: 703-709.
111. Thomas MC, Moran J, Forsblom C et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 2011; 34: 861-866.
112. Vegter S, Perna A, Postma MJ et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23: 165-173.
113. Lambers Heerspink HJ, Holtkamp FA, Parving HH et al. Moderation of dietary sodium potentiates The renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82: 330-337.